Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021)
Johnson & Johnson's (JNJ) quarterly Construction in Progress came in at $4.3 billion in Q1 2021, up 18.67% year-on-year from $3.6 billion in Q1 2020, and up 18.67% quarter-over-quarter from $3.6 billion in Q4 2019.
Johnson & Johnson (JNJ) Construction in Progress (2010 - 2021) Analysis & Trends
Johnson & Johnson has disclosed Construction in Progress across 10 years of filings, most recently posting $4.3 billion for Q1 2021.
- Construction in Progress for Q1 2021 came in at $4.3 billion, up 18.67% year-over-year; the trailing twelve-month figure through Jan 2021 was $4.3 billion (up 18.67% YoY), and the FY2021 annual result was $4.3 billion, up 18.67% from the prior year.
- Construction in Progress came in at $4.3 billion for Q1 2021 at Johnson & Johnson, up from $3.6 billion in the prior quarter.
- In the past five years, Construction in Progress ranged from a high of $4.3 billion in Q1 2021 to a low of $3.4 billion in Q1 2017.
- The 4-year median for Construction in Progress is $3.6 billion (2019), against an average of $3.7 billion.
- Across the five-year window, Construction in Progress slipped 6.17% in 2019 and rose 18.67% in 2021, its largest moves.
- Johnson & Johnson's Construction in Progress stood at $3.4 billion in 2017, then gained by 12.41% to $3.9 billion in 2018, then retreated by 6.17% to $3.6 billion in 2019, then advanced by 18.67% to $4.3 billion in 2021.
- The last three Construction in Progress figures came in at $4.3 billion (Q1 2021), $3.6 billion (Q4 2019), and $3.9 billion (Q4 2018), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,134,969.93 Bn | 92,134,964.97 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 1,027.45 Bn | 1,022.17 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 559.08 Bn | 537.03 Bn | 15.96 Bn | - |
| 4 | AbbVie | 394.75 Bn | 385.40 Bn | 10.78 Bn | - |
| 5 | Merck | 295.12 Bn | 289.47 Bn | 12.09 Bn | - |
| 6 | Amgen | 186.65 Bn | 174.61 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 159.22 Bn | 151.50 Bn | 5.52 Bn | - |
| 8 | Pfizer | 146.00 Bn | 133.23 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 113.22 Bn | 102.77 Bn | 8.07 Bn | 1.54 Bn |
| 10 | Novartis Ag | 108.02 Bn | 107.33 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 3, 2021 | 4.32 Bn |
| Dec 29, 2019 | 3.64 Bn |
| Dec 30, 2018 | 3.88 Bn |
| Dec 31, 2017 | 3.45 Bn |
| Jan 1, 2017 | 3.35 Bn |
| Jan 3, 2016 | 3.53 Bn |
| Dec 28, 2014 | 3.60 Bn |
| Dec 29, 2013 | 3.30 Bn |
| Dec 30, 2012 | 2.74 Bn |
| Jan 1, 2012 | 2.50 Bn |
| Jan 2, 2011 | 2.58 Bn |
| Jan 3, 2010 | 2.52 Bn |